CD4 and infection: Thus, we evaluated the impact of the combination of TLR7 agonist GS-986, a very close analog of vesatolimod, and two bnAbs targeting different regions of the HIV envelope- CD4 binding site by N6-LS [9] and V3 glycan by PGT121 [10] in delaying viral rebound during ART interruption in rhesus macaques that were initiated on viral suppressive ART 14 days post SHIV-1157ipd3N4 infection.